Investigating genetic factors in severe infections
Official title: Genetic Susceptibility to Severe Infections Including in Particular But Not Exhaustively All Types of Viral, Bacterialn and Fungal Infections.
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT06102070 · Data updated 2026-11-12
This study is trying to find out if certain genes make some people more likely to get severe infections than others by looking at patients with rare and serious infections.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 1 site (Paris, Île-de-France Region) |
| Status | Recruiting |
| Started | February 18, 2022 |
| Main results expected | February 17, 2037 |
| Study ends | October 18, 2038 |
| Registry record updated | July 7, 2026 |
| Trial ID | NCT06102070 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with proven rare and severe infections who are hospitalized or followed in specialized medical settings.
✕Probably not a fit
Patients with acquired immunodeficiency or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the genetic susceptibility of individuals to severe infections by examining the interplay between genetic and environmental factors that influence immune responses. It will involve recruiting patients with rare and severe infections, focusing on those requiring hospitalization or experiencing chronic infections. Blood samples and skin biopsies will be collected to analyze the underlying genetic factors contributing to these infections. The study seeks to enhance understanding of why some individuals develop severe disease while others do not.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of individuals at risk for severe infections and inform targeted prevention strategies.
How similar studies have gone: While the investigation of genetic susceptibility to infections has been explored, this specific approach focusing on rare infections is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * to sign the informed consent signed by the patient. In the case of a minor patient, consent is signed by the holders of parental authority. In the case of a protected adult patient, the consent is signed by their legal representative. In the case of an adult patient unable to consent at the time of inclusion, consent is signed by a family member. * to have a proven rare and severe infection * to be hospitalized or followed in a specialized hospital department, in the emergency room or in intensive care * to be affiliated to the French Social Security system * for relatives, to be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces Exclusion Criteria * to have an acquired immunodeficiency (having received immunosuppressive treatment in the 3 months preceding the onset of the disease or being HIV positive) * pregnant woman at the time of illness
Where it's running
-
Centre d'Etudes des Déficits Immunitaires (CEDI), Hôpital Necker-Enfants
Paris, Île-de-France Region, France Recruiting
Study contacts
- Study coordinator: Jacinta Md BUSTAMANTE, MD-PhD
- Email: jacinta.bustamante@aphp.fr
- Phone: 01 71 19 60 04
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
International collaboration to collect information on adults hospitalized with acute infections
Researchers will collect health information and biological samples from adults hospitalized with acute infections to see how these infections start, progress, and respond to care.
-
Pharmacogenomics to improve voriconazole dosing for fungal infections
This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.
-
Survey to assess eligibility for infectious disease clinical trials
This study is trying to find out if people are eligible to join clinical trials for infectious diseases like HIV and vaccines by having them fill out a survey about their health and background.
-
L-citrulline to reduce complications in hospitalized young children with fever
This trial will test whether giving L-citrulline versus placebo to hospitalized children aged 1 month to under 5 years who have a moderate-to-high bedside sTREM-1 risk result can reduce death and serious complications.
-
Rapid suPAR blood test to help triage febrile young children
This study will test whether adding a quick suPAR point-of-care blood test to standard IMCI triage helps health workers better spot children aged 2–59 months with fever who need admission or referral.
-
Evaluating high doses of favipiravir in healthy volunteers
This study is testing how well healthy volunteers can tolerate high doses of favipiravir over two weeks to learn more about its safety and how the body processes it.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.